MGF

What it is

Mechano growth factor is summarized here from the public peptide research file, in this site's own wording. Muscle-produced splice variant of IGF-1; a pegylated form (PEG-MGF) is also sold. The material sold on this site is a research vial, not a branded finished drug, and it is not for human or veterinary use.

Regulatory status

Non-FDA-approved peptide sold as a research chemical / performance drug. No. MGF and PEG-MGF are not approved by the FDA; they are research chemicals and performance-enhancing drugs with no approved compounding status. In sport, mechano growth factors are prohibited at all times under the WADA list.

What the research shows

The headline finding recorded for it: Laboratory and cell-based only; no human efficacy trials. The evidence is preclinical. The table below summarizes the studies indexed on PubMed, from cell work to the strongest human finding, which is observational. There are no controlled human trials of MGF or PEG-MGF for muscle or recovery, and the pegylated form specifically is uncharacterized. The marketed benefit is unproven in people. The muscle-repair rationale rests on laboratory and cell studies, there is no human efficacy evidence, and the pegylated form sold on the market is uncharacterized. Mechano growth factor (MGF, also called IGF-1Ec) is a variant of the IGF-1 gene produced in muscle that has been mechanically loaded or damaged. It has a unique tail region distinct from the IGF-1 that circulates in the blood. In the performance market it is sold as a muscle-repair peptide, frequently as a pegylated version (PEG-MGF) claimed to last longer. It is not an approved medicine. MGF is proposed to act on muscle stem cells (satellite cells), activating them and helping them multiply and delay aging, which would support muscle repair and growth. This is attributed to its unique tail region, thought to work somewhat differently from the classic IGF-1 growth signal. In human muscle-cell cultures, the MGF peptide enhanced satellite-cell activation and fusion, and laboratory versions promoted cell growth and migration. These are cell and laboratory findings. The pegylated form sold on the market is a modification that has not been characterized as a pharmaceutical. This describes the proposed mechanism, separate from proven outcomes in people.

Evidence limits

Evidence label in the source library: Low research. This page does not give a dose, a route, or a schedule. It is not medical advice and it is not instructions for the research vials on this site.

Reported actions

• Laboratory and cell-based only; no human efficacy trials